In a statement coinciding with the company's annual investor meeting, the company said it is "confident that we are taking the right steps to ensure that Merck is generating profitable sales growth to drive improved returns and even greater cash flow than we do today."

In slides accompanying the meeting, the company said it expects to seek approval for eight new drug applications in 2012 and 2013.